<?xml version="1.0" encoding="UTF-8"?>
<p>Firstly, LMICs are concerned that the samples and data taken from pathogens found in their countries are taken and used without their consent to develop vaccines and medicines that are later priced at levels unaffordable to LMIC countries, preventing the very people who contributed to the treatment development from having access to the treatment ( 
 <xref rid="ref-21" ref-type="bibr">Sedyaningsih 
  <italic>et al.</italic>, 2008
 </xref>). This is the issue that Indonesia raised in 2007, stating that the H5N1 samples sent from Indonesia to the World Health Organisation (WHO) were transferred to commercial pharmaceutical manufacturers without Indonesia’s consent; a vaccine subsequently developed was not affordable or available to citizens of the originating countries such as Indonesia and Thailand ( 
 <xref rid="ref-14" ref-type="bibr">Hong, 2018</xref>). More recently, there were widely reported incidents of scientists from the countries of origin of viral samples being unable to access the samples exported to laboratories in developed countries ( 
 <xref rid="ref-24" ref-type="bibr">Telegraph, 2019</xref>). These samples, which remain linked to the patients’ personal data, were admittedly taken and exported to these countries without consent for research from the patients. There are several other incidences of countries refusing permission to share viral samples – both during the Ebola epidemic and the Yellow Fever epidemic in 2016. ( 
 <xref rid="ref-1" ref-type="bibr">Abramowitz 
  <italic>et al.</italic>, 2018
 </xref>).
</p>
